Correction to: Adv Ther (2020) 37:745–758 https://doi.org/10.1007/s12325-019-01198-9
In the original article, the reference 4 has been published and cited incorrectly. The correct reference 4 is “Lorbrena® (lorlatinib) tablets. [Prescribing Information]. Pfizer Labs”. Additionally, reference 4 was cited in error in the Discussion section of the original article (page 755, column 2, paragraph 2, sentence 1). The corrected sentence is as follows: "When used in drug-drug interaction studies to elicit metabolic induction, a rifampin dose of 600 mg/day is typically not associated with transaminase elevations [7, 10]."
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, J., Xu, H., Pawlak, S. et al. Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. Adv Ther 37, 4754 (2020). https://doi.org/10.1007/s12325-020-01480-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-020-01480-1